Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA OBESITY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY: NORTH AMERICA OBESITY TREATMENT MARKET
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: NORTH AMERICA OBESITY TREATMENT MARKET
4.5 DRUG
4.6 WORD PIPELINE
5 REGULATORY FRAMEWORK FOR THE NORTH AMERICA OBESITY TREATMENT MARKET
5.1 REGULATORY APPROVAL PATHWAYS
5.2 LICENSING AND REGISTRATION
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF OBESITY
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT
6.2 RESTRAINTS
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES
7 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)
7.2.1 GLP-1 RECEPTOR AGONISTS
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS
7.2.2.1 Phentermine
7.2.2.2 Phentermine-Topiramate
7.2.2.3 Naltrexone-Bupropion
7.2.3 LIPASE INHIBITORS
7.2.4 DEOXYCHOLIC ACID
7.2.5 OTHERS
7.3 BARIATRIC SURGERY
7.3.1 RESTRICTIVE SURGERIES
7.3.1.1 Sleeve gastrectomy
7.3.1.2 Adjustable gastric banding
7.3.2 COMBINATION SURGERIES
7.3.2.1 Roux-en-Y gastric bypass (RYGB)
7.3.2.2 Mini-gastric bypass (MGB)
7.3.3 MALABSORPTIVE SURGERIES
7.3.3.1 Laparoscopic Surgery
7.3.3.2 Robotic-Assisted Surgery
7.3.3.3 Open Surgery
7.4 BEHAVIORAL & LIFESTYLE THERAPY
7.4.1 DIETARY INTERVENTIONS
7.4.2 BEHAVIORAL MODIFICATION THERAPY
7.4.3 PHYSICAL ACTIVITY PROGRAMS
7.4.4 PSYCHOLOGICAL COUNSELING
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)
7.5.2 INTRAGASTRIC BALLOON (IGB)
7.5.2.1 Orbera intragastric balloon
7.5.2.2 Spatz adjustable balloon system
7.5.3 ASPIRATION THERAPY (ASPIREASSIST)
7.5.4 TRANSORAL GASTROPLASTY (TOGA)
7.6 MEDICAL DEVICES & TECHNOLOGIES
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)
8 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 ADULT OBESITY TREATMENT
8.3 GERIATRIC OBESITY TREATMENT
8.4 PEDIATRIC OBESITY TREATMENT
9 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACIES
9.3 RETAIL PHARMACIES
9.4 WEIGHT MANAGEMENT CLINICS
9.5 HOSPITAL PHARMACIES
9.6 WELLNESS & FITNESS CENTERS
10 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 CLASS III
10.3 CLASS II
10.4 CLASS I
11 NORTH AMERICA OBESITY TREATMENT MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 MEXICO
11.1.3 CANADA
12 NORTH AMERICA OBESITY TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVO NORDISK A/S
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ELI LILLY AND COMPANY
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT/NEWS
14.3 MEDTRONIC
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION
14.4.1 COMPANY SNAPSHOTS
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 JOHNSON & JOHNSON SERVICES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT/NEWS
14.6 ALTIMMUNE
14.6.1 COMPANY SNAPSHOT
14.6.2 PIPELINE PORTFOLIO
14.6.3 RECENT UPDATES
14.7 ASTRAZENECA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT/NEWS
14.8 ALLURION
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
1.1.5 RECENT DEVELOPMENT/NEWS 210
14.9 AMGEN
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
1.1.13 RECENT DEVELOPMENT/NEWS 215
14.1 ARENA PHARMACEUTICALS LTD
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CURRAX PHARMACEUTICALS LLC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 COUSIN SURGERY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT/NEWS
14.14 FITTERFLY HEALTHTECH PVT. LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MORPHIC MEDICAL, INC
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 NOOM, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 OMADA HEALTH INC
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 RESHAPE LIFESCIENCES
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
1.1.7 RECENT DEVELOPMENT/NEWS 234
14.19 RAZIEL
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 SPATZ FGIA INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 SANOFI
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 SANIONA
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 USGI MEDICAL
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENT
14.24 VIVUS LLC.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT/NEWS
14.25 VIKING THERAPEUTICS
14.25.1 COMPANY SNAPSHOTS
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT
14.26 ZEALAND PHARMA
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT/NEWS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)
TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)
TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)
TABLE 4 NORTH AMERICA CLINICAL TRIAL MARKET FOR OBESITY TREATMENT
TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE NORTH AMERICA OBESITY TREATMENT MARKET
TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE NORTH AMERICA OBESITY TREATMENT MARKET
TABLE 7 NORTH AMERICA OBESITY STATISTICS (2022)
TABLE 8 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 53 U.S. OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 U.S. PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 U.S. CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 U.S. RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 U.S. COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 60 U.S. BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 U.S. NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 U.S. INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 U.S. MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 U.S OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 65 U.S. OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 66 U.S. OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MEXICO OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MEXICO CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MEXICO RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 MEXICO COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 73 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 74 MEXICO BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MEXICO NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MEXICO INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MEXICO MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 MEXICO OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 79 MEXICO OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 MEXICO OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 CANADA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 CANADA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 CANADA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 CANADA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 CANADA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 88 CANADA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 CANADA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 CANADA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 CANADA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 CANADA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 93 CANADA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 94 CANADA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA OBESITY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA OBESITY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA OBESITY TREATMENT MARKET: LIFELINE CURVE
FIGURE 7 NORTH AMERICA OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA OBESITY TREATMENT MARKET EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 FIVE SEGMENTS COMPRISE THE NORTH AMERICA OBESITY TREATMENT MARKET , BY TREATMENT TYPE
FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF NORTH AMERICA OBESITY TREATMENT MARKET FROM 2025 TO 2032
FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA OBESITY TREATMENT MARKET IN 2025 - 2032
FIGURE 17 MARKET OVERVIEW
FIGURE 18 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.
FIGURE 19 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)
FIGURE 20 NORTH AMERICA OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 21 NORTH AMERICA OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 22 NORTH AMERICA OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 23 NORTH AMERICA OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA OBESITY TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 25 NORTH AMERICA OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 26 NORTH AMERICA OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 27 NORTH AMERICA OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 28 NORTH AMERICA OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 NORTH AMERICA OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 30 NORTH AMERICA OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 NORTH AMERICA OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 NORTH AMERICA OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024
FIGURE 33 NORTH AMERICA OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 34 NORTH AMERICA OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)
FIGURE 35 NORTH AMERICA OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA OBESITY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 37 NORTH AMERICA OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
